How to appeal a Cigna specialty biologics denial

The framework that applies to your appeal

Federal law gives you the right to a full and fair internal appeal, then an external review by an independent third party.

Cigna-specific note: Sold its Medicaid Advantage book to HCSC in 2023. Express Scripts (PBM) is Cigna-owned. Frequent class-action litigation around mental health parity.

What Cigna's policy requires for specialty biologics

Cited policy: Cigna coverage policy - Janus Kinase Inhibitors

Per FDA BBW post-ORAL Surveillance — JAKi only after failure of >=1 TNFi (FDA-mandated language for RA, PsA, axSpA, UC). Adequate TNFi trial >=12 weeks at therapeutic dose.

How Cigna denies specialty biologics — and how to counter it

Where Cigna pushes back: 1) No prior TNFi failure documented; 2) Adalimumab-adbm (Cyltezo) preferred — Humira not covered; 3) Treatment plan does not include concurrent MTX where indicated.

Counter-arguments that hold up: TNFi contraindication exemption: latent TB unable to complete prophylaxis, demyelinating disease, NYHA III/IV CHF, recurrent serious infection — FDA label does NOT require TNFi trial when contraindicated. ORAL Surveillance caveat: risk applies specifically to RA patients >=50 with >=1 CV risk factor; if outside that population, JAKi remains acceptable per ACR 2021. ESI biosimilar mandate has medical-necessity exception via Accredo: document immunogenicity concern, pediatric stability, prior biosimilar AE.

What Cigna typically denies for specialty biologics

Across Cigna's commercial and Medicare books, denials cluster around a small number of patterns. For specialty biologics, expect:

• Mental health parity violations
• Step therapy
• Specialty drug prior auth
• OON balance billing disputes

Treatments most often denied in this category

These are the specialty biologics treatments most often flagged for prior auth, step therapy, or medical necessity review:

• Humira
• Enbrel
• Remicade
• Stelara
• Skyrizi
• Cosentyx

How to submit the appeal to Cigna

1. Read the denial letter — note the exact denial reason code and the appeal deadline (180 days from the date on the letter).
2. Gather supporting documentation: physician letter of medical necessity, relevant clinical notes, peer-reviewed citations supporting the treatment for your indication, and the policy or coverage document Cigna cited in the denial.
3. File the appeal through Cigna's portal (members: https://my.cigna.com ; providers: https://cignaforhcp.cigna.com). Standard decision returns within 30 days; expedited urgent appeals return within 72 hours.
4. If denied again, request external review by an independent reviewer within 4 months of the final internal denial. In CT, the state insurance department coordinates external review for fully-insured plans; ERISA self-funded plans use a federal external review through DOL/EBSA.

Clinician or prior-auth team handling this on the practice side? See Cigna's prior-authorization criteria by drug: Cigna PA criteria on ApprovalHelp.